A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

September 23, 2024

Primary Completion Date

July 30, 2025

Study Completion Date

September 30, 2025

Conditions
ObesityOverweight and Obesity
Interventions
DRUG

MDR-001

Oral administration of small molecule MDR-001 tablets

DRUG

Placebo

Administered orally placebo

Trial Locations (19)

Unknown

The Second Hospital Of Anhui Medical University, Hefei

The People's Hospital of Suancheng City, Xuancheng

Zibo Central Hospital, Zibo

Peking University People's Hospital, Beijing

The Third People's Hospital of Hainan, Haikou

The Second Hospital Of Hebe Medical University, Shijiazhuang

The Fourth Affiliated Hospital of Harbin Medical University, Harbin

The first Affiliated Hospital of Henan University of Science and Technology, Luoyang

The First Affiliated Hospital of Nanyang Medical College, Nanyang

The First People's Hospital of Chenzhou City, Chenzhou

Zhuzhou Central Hospital, Zhuzhou

Second Hospital of Jilin University, Changchun

Daqing People's Hospital, Daqing

Panjin Liaoyou Gem Flower Hospital, Panjin

The Fifth People's Hospital of Shenyang, Shenyang

Central hospital of Jinan, Jinan

Shanxi Bethune Hospital, Taiyuan

Xianyan Hospital of Yanan Univisity, Xianyang

Yichang Central People's Hospital, Yichang

All Listed Sponsors
lead

MindRank AI Ltd

INDUSTRY

NCT06606483 - A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight | Biotech Hunter | Biotech Hunter